FeesSafety
Pluang+

First Watch reports Q3 revenue up 10.7%, net income $4.8M, and opens 16 new restaurants.

Company Fundamentals
03 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
First Watch reports Q3 revenue up 10.7%, net income $4.8M, and opens 16 new restaurants.

First Watch Restaurant Group reported a 10.7% increase in total revenues to $349.9 million for Q3 2026, with net income rising to $4.8 million from $3.0 million the previous year. The company opened 16 new restaurants across 11 states, bringing the total to 681 locations. Same-restaurant sales grew by 1.0%, and Adjusted EBITDA increased to $39.7 million, prompting an upward revision of the full-year 2026 Adjusted EBITDA outlook to about $136 million. This growth reflects strong operational execution and expansion plans, with 60 net new restaurants expected by year-end.

First Watch Restaurant Group's Q3 2026 results provide context for consumer cyclical stocks. For readers following this sector, here is Pluang's market snapshot as of Nov 03, 2026 19:01 WIB: Among 134 priced Consumer Cyclical-sector US stocks tradable on Pluang, 43 rose and 80 fell. Notable movers include BALL at USD 66.53 with a 1-day change of -2.26%, BBWI at USD 22.68 with a 1-day change of -2.20% and 100% sell order activity, and DHI at USD 149.60 with a 1-day change of -2.18% and 100% buy order activity. The most notable figure is BBWI's full sell order activity on Pluang.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App